Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients

Cancer

Volumn 120, Issue 23, 2014, Pages 3691-3698

  Su, Hui Chun Irene ^a   Haunschild, Carolyn ^a   Chung, Karine ^b   Komrokian, Sara ^c   Boles, Sarah ^a   Sammel, Mary Dupuis ^d   DeMichele, Angela ^c,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antimullerian hormone; Breast cancer; Chemotherapy; Ovarian reserve

Indexed keywords

AROMATASE INHIBITOR; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FOLLITROPIN; GONADORELIN AGONIST; INHIBIN B; MUELLERIAN INHIBITING FACTOR; PACLITAXEL; TAMOXIFEN; ANTINEOPLASTIC AGENT; ESTRADIOL; INHIBIN;

ADULT; AGE; ARTICLE; BODY MASS; BODY SIZE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; COUNSELING; FEMALE; FEMALE FERTILITY; FOLLOW UP; HAZARD RATIO; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OUTPATIENT DEPARTMENT; OVARIAN RESERVE; OVARY FUNCTION; PREDICTION; PROSPECTIVE STUDY; BLOOD; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMICALLY INDUCED; CONVALESCENCE; FEMALE INFERTILITY; MIDDLE AGED; PREMATURE OVARIAN FAILURE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; YOUNG ADULT;

ADULT; AGE FACTORS; ANTI-MULLERIAN HORMONE; ANTINEOPLASTIC AGENTS; BODY SIZE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COHORT STUDIES; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INFERTILITY, FEMALE; INHIBINS; LONGITUDINAL STUDIES; MIDDLE AGED; OVARIAN RESERVE; PRIMARY OVARIAN INSUFFICIENCY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; RISK ASSESSMENT; YOUNG ADULT;

EID: 84913607805     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28942     Document Type: Article

References (37)

1. American Cancer Society. Cancer Facts & Figures 2013. Atlanta, GA: American Cancer Society; 2013.
2. Nicosia SV, Matus-Ridley M, Meadows AT. Gonadal effects of cancer therapy in girls. Cancer. 1985; 55:2364-2372.
3. Su HI, Sammel MD, Green J, et al. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer. 2010; 116:592-599.
4. Letourneau JM, Ebbel EE, Katz P.P., et al. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer. 2012; 118: 1933-1939.
5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast Cancer, v2.2007 [serial online]. Fort Washington, PA: NCCN; 2012. Available at: http://www.nccn.org. Accessed July 17, 2014.
6. Anderson RA, Cameron DA. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab. 2011; 96:1336-1343.
7. Anders C, Marcom PK, Peterson B, et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest. 2008; 26:286-295.
8. Su HI, Sammel MD, Velders L, et al. Association of cyclophospha-mide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. Fertil Steril. 2010; 94:645-654.
9. Anderson RA, Rosendahl M, Kelsey T.W., Cameron DA. Pretreat-ment anti-Mullerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer. 2013; 49: 3404-3411.
10. Petrek JA, Naughton MJ, Case L.D., et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006; 24:1045-1051.
11. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premeno-pausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006; 24:5769-5779.
12. Byrne J, Fears TR, Gail M.H., et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol. 1992; 166:788-793.
13. Weenen C, Laven JS, Von Bergh AR, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004; 10:77-83.
14. van Disseldorp J, Lambalk CB, Kwee J, et al. Comparison of interand intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod. 2010; 25:221-227.
15. Freeman EW, Sammel MD, Gracia C.R., et al. Follicular phase hormone levels and menstrual bleeding status in the approach to menopause. Fertil Steril. 2005; 83:383-392.
16. Harlow SD, Gass M, Hall J.E., et al. Executive summary of the Stages of Reproductive Aging Workshop 1 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012; 97:1159-1168.
17. Lutchman Singh K, Muttukrishna S, Stein R.C., et al. Predictors of ovarian reserve in young women with breast cancer. Br J Cancer. 2007; 96:1808-1816.
18. Dillon KE, Sammel MD, Prewitt M, et al. Pretreatment antimuller-ian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril. 2013; 99:477-483.
19. Yu B, Douglas N, Ferin M.J., et al. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer. 2010; 116:2099-2105.
20. Anderson RA, Themmen AP, Al-Qahtani A, Groome N.P., Cameron DA. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod. 2006; 21:2583-2592.
21. Brougham MF, Crofton PM, Johnson E.J., Evans N., Anderson RA, Wallace WH. Anti-Mullerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab. 2012; 97:2059-2067.
22. Henry NL, Xia R, Schott A.F., McConnell D., Banerjee M, Hayes DF. Prediction of postchemotherapy ovarian function using markers of ovarian reserve. Oncologist. 2014; 19:68-74.
23. Practice Committee of American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertil Steril. 2008; 90(5 suppl): S219-S225.
24. La Marca A, Sighinolfi G, Radi D., et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010; 16:113-130.
25. Nardo LG, Gelbaya TA, Wilkinson H, et al. Circulating basal anti-Mullerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril. 2009; 92:1586-1593.
26. Jayaprakasan K, Campbell B, Hopkisson J., Johnson I, Raine-Fenning N. A prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril. 2008; 93:855-864.
27. Randolph JF Jr, Sowers M, Gold E.B., et al. Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab. 2003; 88:1516-1522.
28. Gold EB, Crawford SL, Avis N.E., et al. Factors related to age at natural menopause: longitudinal analyses from SWAN. Am J Epidemiol. 2013; 178:70-83.
29. Moons KG, Kengne AP, Woodward M, et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart. 2012; 98:683-690.
30. Kumar A, Kalra B, Patel A., McDavid L, Roudebush WE. Development of a second generation anti-Mullerian hormone (AMH) ELISA. J Immunol Methods. 2010; 362:51-59.
31. Willett W, Stampfer MJ, Bain C, et al. Cigarette smoking, relative weight, and menopause. Am J Epidemiol. 1983; 117:651-658.
32. Rodstrom K, Bengtsson C, Milsom I., Lissner L, Sundh V, Bjourkelund C. Evidence for a secular trend in menopausal age: a population study of women in Gothenburg. Menopause. 2003; 10: 538-543.
33. Broer SL, Eijkemans MJ, Scheffer G.J., et al. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab. 2011; 96:2532-2539.
34. Freeman EW, Sammel MD, Lin H, Gracia CR. Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women. J Clin Endocrinol Metab. 2012; 97:1673-1680.
35. Tehrani FR, Shakeri N, Solaymani-Dodaran M, Azizi F. Predicting age at menopause from serum antimullerian hormone concentration. Menopause. 2011; 18:766-770.
36. Santoro N, Brockwell S, Johnston J., et al. Helping midlife women predict the onset of the final menses: SWAN, the Study of Women's Health Across the Nation. Menopause. 2007; 14:415-424.
37. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer. 1995; 72: 511-518.